Page last updated: 2024-12-07

l 670596

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 670596: thromboxane and prostaglondin endoperoxide receptor antagoist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129360
CHEMBL ID4303193
CHEBI ID91930
SCHEMBL ID3044967
MeSH IDM0169989

Synonyms (32)

Synonym
l 670596
HMS3268M18
l-670596
L002392
2-[6,8-difluoro-9-[(4-methylsulfonylphenyl)methyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid
l-670,596
121083-05-4
1h-carbazole-1-acetic acid, 6,8-difluoro-2,3,4,9-tetrahydro-9-((4-(methylsulfonyl)phenyl)methyl)-, (-)-
(-)-6-8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1h-carbazole-1-acetic acid
BRD-A85472596-001-01-4
AKOS022180202
SCHEMBL3044967
(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1h-carbazole-1-acetic acid
1h-carbazole-1-aceticacid,6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-,(-)-
J-004444
sr-01000597550
SR-01000597550-1
CHEBI:91930
(6,8-difluoro-9-{[4-(methanesulfonyl)phenyl]methyl}-2,3,4,9-tetrahydro-1h-carbazol-1-yl)acetic acid
DTXSID40923668
FT-0757831
Q27163729
2-(6,8-difluoro-9-(4-(methylsulfonyl)benzyl)-2,3,4,9-tetrahydro-1h-carbazol-1-yl)acetic acid
HMS3676N08
l-670,596;l 670596;l670596;l670,596;l 670,596
BCP28232
HMS3412N08
CHEMBL4303193
(-)-6-8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1h-carbazole-1-aceticacid
2-(6,8-difluoro-9-(4-(methylsulfonyl)benzyl)-2,3,4,9-tetrahydro-1h-carbazol-1-yl)aceticacid
CS-0029171
HY-108561
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.00)18.7374
1990's14 (70.00)18.2507
2000's3 (15.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]